Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry".
Review published in Medicina clinica (2024)
Abstract
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in a group of patients that presented with multiorgan involvement and microangiopathic features of APS. Most of the current knowledge of CAPS comes from the analysis of all cases collected at the "CAPS Registry" that was created in 2000 to perform studies on this condition. Most cases are triggered by a prothrombotic situation that leads to a multiorgan thrombosis and a cytokine storm. The analysis of cases included in the "CAPS Registry" has shown that the triple therapy with anticoagulation, glucocorticoids, and plasma exchange and/or intravenous immunoglobulins is associated to a better prognosis of CAPS. The improvement of the knowledge allowed a decrease from the 50% mortality rate reported in the first series to 25-30% in the most recent publications.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in a group of patients that presented with multiorgan involvement and...
Warum dies für die Hirudotherapie relevant ist
Dieser Review stützt sich auf das internationale CAPS-Register, um den Wissensstand zum katastrophalen Antiphospholipid-Syndrom zusammenzufassen, und stellt fest, dass eine Tripeltherapie mit Antikoagulation, Glukokortikoiden sowie Plasmapherese und/oder intravenösen Immunglobulinen die Prognose verbessert und die Mortalität von etwa 50 % auf 25–30 % senkt. Er ist für das ASH-Gebiet nur im weiteren Kontext der Antikoagulation als Teil eines therapeutischen Regimes bei thrombotischer Erkrankung relevant. Der Abstract erwähnt weder Blutegel, Hirudotherapie noch Hirudin-basierte Wirkstoffe. Seine Relevanz ist indirekt.
Zitation
Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry".
Rodriguez-Pintó et al. · Medicina clinica, 2024
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026